Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-04-07
DOI
10.3389/fphar.2022.805388
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DNA Methylation: A Promising Approach in Management of Alzheimer’s Disease and Other Neurodegenerative Disorders
- (2022) Gagandeep Kaur et al. Biology-Basel
- Advances in neurochemical measurements: A review of biomarkers and devices for the development of closed-loop deep brain stimulation systems
- (2021) Juan M. Rojas Cabrera et al. REVIEWS IN ANALYTICAL CHEMISTRY
- Neuroprotective potential of cinnamon and its metabolites in Parkinson's disease: Mechanistic insights, limitations, and novel therapeutic opportunities
- (2021) Efthalia Angelopoulou et al. JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
- Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
- (2021) Robert A. Hauser et al. Frontiers in Neurology
- Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis
- (2021) Ahmed Negida et al. NEUROLOGICAL SCIENCES
- Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery
- (2021) Javed Ahmad et al. BIOCHEMICAL PHARMACOLOGY
- Levodopa-Induced Ocular Dyskinesia in an Early-Onset Parkinson Disease Patient With GBA Mutation
- (2021) Jia-Ming He et al. CLINICAL NEUROPHARMACOLOGY
- Neuroprotective Potential of Chrysin: Mechanistic Insights and Therapeutic Potential for Neurological Disorders
- (2021) Awanish Mishra et al. MOLECULES
- Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease
- (2021) Rie Tohge et al. NEUROPHARMACOLOGY
- Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review
- (2021) Michał Hutny et al. Journal of Clinical Medicine
- Role of curcumin and its nanoformulations in neurotherapeutics: A comprehensive review
- (2020) Mukesh Mandal et al. JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
- Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on l-DOPA-induced dyskinesia in parkinsonian rats
- (2020) Keita Arakawa et al. Pharmacological Reports
- EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
- (2020) Caroline M. Tanner et al. Journal of Parkinsons Disease
- 6‐hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata
- (2020) S. Vegas‐Suárez et al. BRITISH JOURNAL OF PHARMACOLOGY
- Role of flavonoids in neurodegenerative diseases: Limitations and future perspectives
- (2020) Gagandeep Maan et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease
- (2020) Rhyomi C. Sellnow et al. JOURNAL OF NEUROSCIENCE
- Research advances on L-DOPA-induced dyskinesia: from animal models to human disease
- (2020) Xi Chen et al. NEUROLOGICAL SCIENCES
- The Noradrenergic System in Parkinson’s Disease
- (2020) Elena Paredes-Rodriguez et al. Frontiers in Pharmacology
- Self-assembled polydopamine nanoparticles improve treatment in Parkinson's disease model mice and suppress dopamine-induced dyskinesia
- (2020) Long Binh Vong et al. Acta Biomaterialia
- Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis
- (2020) Caroline D. Binde et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- µ opioid receptor agonism for L-DOPA-induced dyskinesia in Parkinson’s disease
- (2020) Erwan Bezard et al. JOURNAL OF NEUROSCIENCE
- Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding
- (2020) Mario Meloni et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
- (2020) Isabel Espadas et al. NEUROBIOLOGY OF DISEASE
- Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia
- (2020) Valeria Calabrese et al. Frontiers in Aging Neuroscience
- PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease
- (2020) Seong-Jin Yu et al. Frontiers in Neuroscience
- Rho kinase inhibitor fasudil reduces L‐DOPA‐induced dyskinesia in a rat model of Parkinson´s disease
- (2020) Andrea Lopez‐Lopez et al. BRITISH JOURNAL OF PHARMACOLOGY
- Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities
- (2020) C. Warren Olanow et al. MOVEMENT DISORDERS
- Dopamine D1 receptor signalling in dyskinetic Parkinsonian rats revealed by fiber photometry using FRET-based biosensors
- (2020) Jace Jones-Tabah et al. Scientific Reports
- The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson’s Disease
- (2020) Feras Altwal et al. Cells
- 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology
- (2020) Massimo E. Maffei INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Zonisamide for the Treatment of Parkinson Disease: A Current Update
- (2020) Chengqian Li et al. Frontiers in Neuroscience
- Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease
- (2019) Constant V.M. Verschuur et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effects of zonisamide on L-DOPA–induced dyskinesia in Parkinson's disease model mice
- (2019) Hiromi Sano et al. NEUROCHEMISTRY INTERNATIONAL
- Abnormal cortical facilitation and L-dopa-induced dyskinesia in Parkinson's disease
- (2019) Andrea Guerra et al. Brain Stimulation
- Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia
- (2019) Thomas Müller et al. DRUGS
- Immunomodulatory drugs alleviate l ‐dopa‐induced dyskinesia in a rat model of Parkinson's disease
- (2019) Laura Boi et al. MOVEMENT DISORDERS
- The impact of levodopa therapy-induced complications on quality of life in Parkinson’s disease patients in Singapore
- (2019) Jonathan Wu et al. Scientific Reports
- Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa–Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson’s Rats
- (2019) Wen-Wen Wang et al. Frontiers in Pharmacology
- Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects
- (2019) Albarrán-Bravo et al. Biomolecules
- Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update
- (2019) Valentina Leta et al. Expert Opinion On Drug Safety
- Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism
- (2019) Imane Frouni et al. NEUROPHARMACOLOGY
- Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats
- (2019) Zeng-Rui Zhang et al. NEUROCHEMISTRY INTERNATIONAL
- Cerebellar continuous theta burst stimulation reduces levodopa-induced dyskinesias and decreases serum BDNF levels
- (2019) Angela Sanna et al. NEUROSCIENCE LETTERS
- Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism
- (2019) Masatoshi Ogawa et al. Frontiers in Neurology
- Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l -Dopa-induced wearing-off and abnormal involuntary movements
- (2018) Hiroko Tsunekawa et al. BEHAVIOURAL BRAIN RESEARCH
- mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia
- (2018) Irene Sebastianutto et al. CURRENT OPINION IN PHARMACOLOGY
- Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia
- (2018) Keila Bariotto-dos-Santos et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Adaptive deep brain stimulation for Parkinson’s disease using motor cortex sensing
- (2018) Nicole C Swann et al. Journal of Neural Engineering
- The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective
- (2018) Manolo Carta et al. JOURNAL OF NEURAL TRANSMISSION
- Deep brain stimulation outcomes in patients implanted under general anesthesia with frame-based stereotaxy and intraoperative MRI
- (2018) Caio M. Matias et al. JOURNAL OF NEUROSURGERY
- Magnetic resonance–guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson's disease and essential tremor cases
- (2018) Menashe Zaaroor et al. JOURNAL OF NEUROSURGERY
- International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
- (2018) Susan H. Fox et al. MOVEMENT DISORDERS
- Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson’s Disease
- (2018) Julia Paik et al. CNS DRUGS
- Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going
- (2018) Aldo Quattrone et al. MOVEMENT DISORDERS
- The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia
- (2018) Andrew J. Flores et al. NEUROPHARMACOLOGY
- Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?
- (2018) Susan H. Fox et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson’s disease
- (2018) Fabrizio Stocchi et al. Expert Opinion on Drug Metabolism & Toxicology
- Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia
- (2018) F. Gardoni et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats
- (2018) Samantha M. Meadows et al. MOVEMENT DISORDERS
- Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial
- (2018) Jean-Christophe Corvol et al. PARKINSONISM & RELATED DISORDERS
- A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease
- (2017) Wai Kin D. Ko et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l -DOPA-induced dyskinesia in 6-OHDA-lesioned rats
- (2017) Elisabetta Tronci et al. EXPERIMENTAL NEUROLOGY
- Using Wearable Technology to Generate Objective Parkinson’s Disease Dyskinesia Severity Score: Possibilities for Home Monitoring
- (2017) Mehdi Delrobaei et al. IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING
- Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study
- (2017) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease
- (2017) Susan H. Fox et al. MOVEMENT DISORDERS
- Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)
- (2017) Wolfgang Oertel et al. MOVEMENT DISORDERS
- Mucuna pruriens in Parkinson disease
- (2017) Roberto Cilia et al. NEUROLOGY
- The Safety and Efficacy of Using the O-Arm Intraoperative Imaging System for Deep Brain Stimulation Lead Implantation
- (2017) Leonardo A. Frizon et al. NEUROMODULATION
- Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats
- (2017) Mitsuaki Oki et al. NEUROSCIENCE RESEARCH
- Pallidal stimulation in Parkinson's patients with contraindications to subthalamic target: A 3 years follow-up
- (2017) Julien Bonenfant et al. PARKINSONISM & RELATED DISORDERS
- Contribution of the nitric oxide donor molsidomine and the antiparkinsonian drug l-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats
- (2017) Elżbieta Lorenc-Koci et al. Pharmacological Reports
- Striatal Gαolf/cAMP Signal-Dependent Mechanism to Generate Levodopa-Induced Dyskinesia in Parkinson’s Disease
- (2017) Satoshi Goto Frontiers in Cellular Neuroscience
- Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease
- (2017) Ying Wan et al. Frontiers in Aging Neuroscience
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)
- (2017) Rajesh Pahwa et al. JAMA Neurology
- Adverse events in deep brain stimulation: A retrospective long-term analysis of neurological, psychiatric and other occurrences
- (2017) Carsten Buhmann et al. PLoS One
- The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats
- (2016) C Miguelez et al. BRITISH JOURNAL OF PHARMACOLOGY
- mGlu5, Dopamine D2and Adenosine A2AReceptors in L-DOPA-induced Dyskinesias
- (2016) Nicolas Morin et al. Current Neuropharmacology
- Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia
- (2016) Dhanya Vijayakumar et al. DRUGS
- Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease
- (2016) Florence C.F. Chang et al. JOURNAL OF CLINICAL NEUROSCIENCE
- The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in L-DOPA-Induced Dyskinesia in Parkinsonian Rats
- (2016) D. Lindenbach et al. JOURNAL OF NEUROSCIENCE
- Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson’s disease
- (2016) Jill L. Ostrem et al. JOURNAL OF NEUROSURGERY
- Mavoglurant in Parkinson's patients withl-Dopa-induced dyskinesias: Two randomized phase 2 studies
- (2016) Claudia Trenkwalder et al. MOVEMENT DISORDERS
- A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia
- (2016) Claudia Trenkwalder et al. MOVEMENT DISORDERS
- A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
- (2016) François Tison et al. MOVEMENT DISORDERS
- Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease
- (2016) Kristin B. Dupre et al. NEUROBIOLOGY OF DISEASE
- GPi vs STN deep brain stimulation for Parkinson disease
- (2016) Vincent J.J. Odekerken et al. NEUROLOGY
- The decade after subthalamic stimulation in advanced Parkinson's disease: A balancing act
- (2016) Asha Kishore et al. NEUROLOGY INDIA
- Effects of neurostimulation for advanced Parkinson’s disease patients on motor symptoms: A multiple-treatments meta-analysas of randomized controlled trials
- (2016) Cheng-Long Xie et al. Scientific Reports
- Memantine and reduced time with dyskinesia in Parkinson′s Disease
- (2015) K. Wictorin et al. ACTA NEUROLOGICA SCANDINAVICA
- Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease
- (2015) Lisa F. Potts et al. ANNALS OF NEUROLOGY
- NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model
- (2015) Min Kong et al. BEHAVIOURAL BRAIN RESEARCH
- Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies
- (2015) Sabeena Sharma et al. BIOMEDICINE & PHARMACOTHERAPY
- Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate
- (2015) Maude Beaudoin-Gobert et al. BRAIN
- Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
- (2015) Per Svenningsson et al. BRAIN
- Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys
- (2015) D. Gagnon et al. Brain Structure & Function
- Dynamics and modulation of metabotropic glutamate receptors
- (2015) Philippe Rondard et al. CURRENT OPINION IN PHARMACOLOGY
- Motor complications in an incident Parkinson's disease cohort
- (2015) N. W. Scott et al. EUROPEAN JOURNAL OF NEUROLOGY
- The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets
- (2015) Shin-ichi Uchida et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The efficacy of oral adenosine A2Aantagonist istradefylline for the treatment of moderate to severe Parkinson’s disease
- (2015) Ruxandra Julia Vorovenci et al. Expert Review of Neurotherapeutics
- Wearable sensor-based objective assessment of motor symptoms in Parkinson’s disease
- (2015) Christiana Ossig et al. JOURNAL OF NEURAL TRANSMISSION
- Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat
- (2015) Nirmal Bhide et al. JOURNAL OF NEUROCHEMISTRY
- Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and L-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease
- (2015) C. B. Divito et al. JOURNAL OF NEUROSCIENCE
- Parkinson's disease
- (2015) Lorraine V Kalia et al. LANCET
- Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study
- (2015) Miho Murata et al. MOVEMENT DISORDERS
- New treatments for levodopa-induced motor complications
- (2015) Olivier Rascol et al. MOVEMENT DISORDERS
- Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease
- (2015) Giovanna Lopane et al. MOVEMENT DISORDERS
- Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)
- (2015) Rajesh Pahwa et al. MOVEMENT DISORDERS
- Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3−/− aphakia mice
- (2015) Oscar Solís et al. NEUROBIOLOGY OF DISEASE
- Effect of simvastatin on l-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats
- (2015) Tan Wang et al. NEUROLOGICAL SCIENCES
- D3dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia
- (2015) Doris E. Payer et al. NEUROLOGY
- Unilateral magnetic resonance–guided focused ultrasound pallidotomy for Parkinson disease
- (2015) Young Cheol Na et al. NEUROLOGY
- Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist
- (2015) Hanna Iderberg et al. NEUROPHARMACOLOGY
- Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches
- (2015) Haritz Jiménez-Urbieta et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
- (2015) Matthieu F. Bastide et al. PROGRESS IN NEUROBIOLOGY
- The efficacy of oral adenosine A2Aantagonist istradefylline for the treatment of moderate to severe Parkinson’s disease
- (2015) Ruxandra Julia Vorovenci et al. Expert Review of Neurotherapeutics
- Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease
- (2015) Robert A. Hauser et al. JAMA Neurology
- Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the Striatum
- (2015) Huan Du et al. Parkinsons Disease
- MRI Guided Focused Ultrasound Thalamotomy for Moderate-to-Severe Tremor in Parkinson’s Disease
- (2015) Ilana Schlesinger et al. Parkinsons Disease
- Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats
- (2014) D Lindenbach et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
- (2014) Eva Schaeffer et al. CNS DRUGS
- Evaluation of the Efficacy of Pramipexole for Treating Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
- (2014) Hiroya Utsumi et al. INTERNAL MEDICINE
- Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson’s disease
- (2014) Sevgi Sayın et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Motor Impairments, Striatal Degeneration, and Altered Dopamine-Glutamate Interplay in Mice Lacking PSD-95
- (2014) Jingping Zhang et al. JOURNAL OF NEUROGENETICS
- Mechanisms of Dopamine D1 Receptor-Mediated ERK1/2 Activation in the Parkinsonian Striatum and Their Modulation by Metabotropic Glutamate Receptor Type 5
- (2014) T. Fieblinger et al. JOURNAL OF NEUROSCIENCE
- Stem Cells in Neurological Disorders: Emerging Therapy with Stunning Hopes
- (2014) Ghanshyam Upadhyay et al. MOLECULAR NEUROBIOLOGY
- Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease
- (2014) Rupam Borgohain et al. MOVEMENT DISORDERS
- Presynaptic effects of levodopa and their possible role in dyskinesia
- (2014) Eugene V. Mosharov et al. MOVEMENT DISORDERS
- Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease
- (2014) Christopher Kobylecki et al. PARKINSONISM & RELATED DISORDERS
- An Eight-Year Clinic Experience with Clozapine Use in a Parkinson’s Disease Clinic Setting
- (2014) Nawaz Hack et al. PLoS One
- Differential Dopamine Receptor Occupancy Underlies L-DOPA-Induced Dyskinesia in a Rat Model of Parkinson's Disease
- (2014) Gurdal Sahin et al. PLoS One
- Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats
- (2014) Cheng-long Xie et al. Scientific Reports
- Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats
- (2014) SuFang Zhang et al. Scientific Reports
- New treatments for the motor symptoms of Parkinson’s disease
- (2014) Anne-Catherine Vijverman et al. Expert Review of Clinical Pharmacology
- Surgical Treatment of Dyskinesia in Parkinson’s Disease
- (2014) Renato P. Munhoz et al. Frontiers in Neurology
- Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates
- (2014) Nicolas Morin et al. Frontiers in Neurology
- A2A receptor antagonists do not induce dyskinesias in drug-naive or l-dopa sensitized rats
- (2013) N. Jones et al. BRAIN RESEARCH BULLETIN
- Opiate Exposure and Withdrawal Induces a Molecular Memory Switch in the Basolateral Amygdala between ERK1/2 and CaMKII -Dependent Signaling Substrates
- (2013) D. Lyons et al. JOURNAL OF NEUROSCIENCE
- Accuracy of deep brain stimulation electrode placement using intraoperative computed tomography without microelectrode recording
- (2013) Kim J. Burchiel et al. JOURNAL OF NEUROSURGERY
- Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
- (2013) Robert A Hauser et al. LANCET NEUROLOGY
- Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
- (2013) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study
- (2013) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease
- (2013) Chiara Fiorentini et al. NEUROBIOLOGY OF DISEASE
- 5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model
- (2013) Elisabetta Tronci et al. NEUROBIOLOGY OF DISEASE
- Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA
- (2013) Elżbieta Lorenc-Koci et al. NEUROCHEMISTRY INTERNATIONAL
- Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial
- (2013) F. Ory-Magne et al. NEUROLOGY
- Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys
- (2013) Laurent Grégoire et al. PARKINSONISM & RELATED DISORDERS
- The effects of BMY-14802 against l-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat
- (2013) Nirmal Bhide et al. PSYCHOPHARMACOLOGY
- Clinical outcomes of PD patients having bilateral STN DBS using high-field interventional MR-imaging for lead placement
- (2012) Jill L. Ostrem et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Nitric Oxide Modulation of the Basal Ganglia Circuitry: Therapeutic Implication for Parkinson's Disease and Other Motor Disorders
- (2012) Massimo Pierucci et al. CNS & Neurological Disorders-Drug Targets
- Serotonin transporter inhibition attenuatesl-DOPA-induced dyskinesia without compromisingl-DOPA efficacy in hemi-parkinsonian rats
- (2012) Christopher Bishop et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- New pharmacological avenues for the treatment ofl-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors
- (2012) Fabio Blandini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Dopamine- and cAMP-regulated Phosphoprotein of 32-kDa (DARPP-32)-dependent Activation of Extracellular Signal-regulated Kinase (ERK) and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Experimental Parkinsonism
- (2012) Emanuela Santini et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor trafficking
- (2012) Gregory Porras et al. JOURNAL OF CLINICAL INVESTIGATION
- The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice
- (2012) Karl Strecker et al. JOURNAL OF NEURAL TRANSMISSION
- G olf Mutation Allows Parsing the Role of cAMP-Dependent and Extracellular Signal-Regulated Kinase-Dependent Signaling in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia
- (2012) C. Alcacer et al. JOURNAL OF NEUROSCIENCE
- Effect of Selective Serotonin Reuptake Inhibitors via 5-HT1A Receptors on L-DOPA-Induced Rotational Behavior in a Hemiparkinsonian Rat Model
- (2012) Masatoshi Inden et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation
- (2012) Alfonso Fasano et al. LANCET NEUROLOGY
- Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)
- (2012) P. A. LeWitt et al. NEUROLOGY
- Amantadine: The journey from fighting flu to treating Parkinson disease
- (2012) G. Hubsher et al. NEUROLOGY
- Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial
- (2012) O. Rascol et al. PARKINSONISM & RELATED DISORDERS
- Ten-Year Outcome of Subthalamic Stimulation in Parkinson Disease
- (2011) Anna Castrioto ARCHIVES OF NEUROLOGY
- Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias
- (2011) Imtiaz Ahmed et al. BRAIN
- Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials
- (2011) Spyridon Spyros Papapetropoulos CNS Neuroscience & Therapeutics
- Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders
- (2011) Joseph Jankovic et al. Expert Review of Neurotherapeutics
- Serotonergic modulation of receptor occupancy in rats treated with l-DOPA after unilateral 6-OHDA lesioning
- (2011) Adjmal Nahimi et al. JOURNAL OF NEUROCHEMISTRY
- Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease
- (2011) Andrew Lees et al. MOVEMENT DISORDERS
- The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease
- (2011) Klaus Seppi et al. MOVEMENT DISORDERS
- Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease
- (2011) Maurizio Zibetti et al. MOVEMENT DISORDERS
- Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats
- (2011) Christopher J. Barnum et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
- (2011) Véronique Sgambato-Faure et al. PROGRESS IN NEUROBIOLOGY
- MRI-Guided Subthalamic Nucleus Deep Brain Stimulation without Microelectrode Recording: Can We Dispense with Surgery under Local Anaesthesia?
- (2011) Takeshi Nakajima et al. STEREOTACTIC AND FUNCTIONAL NEUROSURGERY
- Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
- (2011) Sylvia Navailles et al. Parkinsons Disease
- Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia
- (2010) Daniella Rylander et al. ANNALS OF NEUROLOGY
- Deletion of adenosine A1 or A2A receptors reduces l-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease
- (2010) Danqing Xiao et al. BRAIN RESEARCH
- Patient perception of dyskinesia in Parkinson's disease
- (2010) S. W. Hung et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
- (2010) Paolo Calabresi et al. LANCET NEUROLOGY
- Effect of histamine H2receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease
- (2010) Tom H. Johnston et al. MOVEMENT DISORDERS
- Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease
- (2010) Elena Moro et al. MOVEMENT DISORDERS
- Long-term antidyskinetic efficacy of amantadine in Parkinson's disease
- (2010) Elisabeth Wolf et al. MOVEMENT DISORDERS
- Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease
- (2010) P. Stathis et al. MOVEMENT DISORDERS
- Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease
- (2010) Ray L. Watts et al. MOVEMENT DISORDERS
- Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease
- (2010) Sylvia Navailles et al. NEUROBIOLOGY OF DISEASE
- Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease
- (2010) Kenneth A. Follett et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Tolerability of Pardoprunox, a New Partial Dopamine Agonist, in a Randomized, Controlled Study of Patients with Advanced Parkinson’s Disease
- (2009) R.A. Hauser et al. EUROPEAN NEUROLOGY
- Treatment of Parkinson’s disease by cortical stimulation
- (2009) Jean-Pascal Lefaucheur Expert Review of Neurotherapeutics
- Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson DiseaseA Randomized Controlled Trial
- (2009) Frances M. Weaver JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia
- (2009) Hanna S. Lindgren et al. JOURNAL OF NEUROCHEMISTRY
- Site-specific action of l-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic l-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats
- (2009) K. Buck et al. NEUROSCIENCE
- Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
- (2008) A. Munoz et al. BRAIN
- Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments
- (2008) Elmyra V. Encarnacion et al. EUROPEAN NEUROLOGY
- Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism
- (2008) John G. Nutt et al. MOVEMENT DISORDERS
- Molecular mechanisms underlying levodopa-induced dyskinesia
- (2008) Paolo Calabresi et al. MOVEMENT DISORDERS
- Placebo influences on dyskinesia in Parkinson's disease
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
- Effect of transcranial magnetic stimulation on Parkinson motor function-Systematic review of controlled clinical trials
- (2008) Behzad Elahi et al. MOVEMENT DISORDERS
- Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease
- (2008) Saša R. Filipović et al. MOVEMENT DISORDERS
- SUBDURAL MOTOR CORTEX STIMULATION FOR CENTRAL AND PERIPHERAL NEUROPATHIC PAIN
- (2008) Maxime Delavallée et al. NEUROSURGERY
- Priming for l-dopa-induced dyskinesia in Parkinson’s disease: A feature inherent to the treatment or the disease?
- (2008) Agnès Nadjar et al. PROGRESS IN NEUROBIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More